You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.


What s apotex s ruxolitinib market share forecast?

See the DrugPatentWatch profile for ruxolitinib

Based on the information provided, I found a source that discusses the patent for Ruxolitinib, a drug manufactured by Apotex. However, it does not provide a specific market share forecast for Apotex's Ruxolitinib. Nonetheless, I can offer some insights into the patent and the drug's market.

Ruxolitinib, under the brand name Jakafi, is a medication used to treat myelofibrosis and polycythemia vera, two rare blood disorders. The drug's patent, held by Incyte Corporation, was set to expire in November 2027 [1]. However, Apotex and Incyte reached a settlement in 2017 that allowed Apotex to launch a generic version of Jakafi in November 2022, with a license to sell it until the end of the patent term in November 2027 [2].

As for the market share forecast, it is difficult to provide an accurate figure without recent data. However, Ruxolitinib has been a significant player in the treatment of myelofibrosis and polycythemia vera, and Apotex's entry into the market with a generic version may impact the drug's market dynamics.

In summary, while I cannot provide a specific market share forecast for Apotex's Ruxolitinib, the drug has a significant role in treating myelofibrosis and polycythemia vera, and Apotex's launch of a generic version may influence the market.


1. (n.d.). Ruxolitinib (Jakafi) Patent Expiration. Retrieved from
2. Incyte Corporation. (2017, November 13). Incyte and Apotex Announce Settlement of Jakafi® (Ruxolitinib) Patent Litigation. Retrieved from

Other Questions About Ruxolitinib :  Could you provide details on the additional substances in ruxolitinib by apotex? Ruxolitinib apotex anda filing date? Are there specific patient populations where ruxolitinib outperforms azacitidine monotherapy?

DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy